Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.68 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA3 | P07451 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30125417 | 1.00 | CYP3A4 (1.00) | CYP3A4PDE10AALOX5NPC1RAB9A | |
| SCHEMBL4035810 | 0.87 | CYP3A4 (0.77) | CYP3A4PDE10AALOX5NPC1RAB9A | |
| SCHEMBL27969047 | 0.86 | CYP3A4 (0.76) | CYP3A4PDE10AALOX5MEN1KMT2A | |
| SCHEMBL1681256 | 0.84 | CYP3A4 (0.73) | CYP3A4PDE10AALOX5NPC1RAB9A | |
| SCHEMBL27357321 | 0.84 | CYP3A4 (0.72) | CYP3A4PDE10AALOX5MEN1KMT2A | |
| SCHEMBL14937684 | 0.82 | CYP3A4 (0.69) | CYP3A4PDE10ANPC1RAB9AMEN1 | |
| SCHEMBL13463310 | 0.82 | CYP3A4 (0.69) | CYP3A4PDE10AALOX5NPC1RAB9A | |
| SCHEMBL23412137 | 0.81 | CYP3A4 (0.68) | CYP3A4PDE10ANPC1RAB9AMEN1 | |
| SCHEMBL51460 | 0.81 | ALOX5 (1.00) | CYP3A4ALOX5NPC1RAB9AMEN1 | |
| Benzene SCHEMBL27935642 | 0.80 | CYP3A4 (0.67) | CYP3A4PDE10AALOX5NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106216-A1 | Method of measuring drug-metabolizing enzyme activity, method of evaluating inhibition of drug-metabolizing enzyme activity, and composition for these methods | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2004-06-03 | — | — | US | claimed |
| EP-1378751-A2 | Method of measuring drug-metabolizing enzyme activity, method of evaluating inhibition of drug-metabolizing enzyme activity, and composition for these methods | Toyo Boseki Kabushiki Kaisha (JP) | 2004-01-07 | — | — | EP | claimed |
| US-20030211565-A1 | Monooxygenase assays | SINGH SHARAT (US) | 2003-11-13 | — | — | US | claimed |
| US-6632630-B2 | Quantitative analysis | ACLARA BIOSCIENCES, INC. | 2003-10-14 | — | — | US | claimed |
| EP-1268848-A2 | MONOOXYGENASE ASSAYS | Aclara BioSciences, Inc. (US) | 2003-01-02 | — | — | EP | claimed |
| US-20020025545-A1 | Monooxygenase assays | MONOGRAM BIOSCIENCES, INC. | 2002-02-28 | — | — | US | claimed |
| WO-2001073113-A2 | MONOOXYGENASE ASSAYS | ACLARA BIOSCIENCES, INC. (US) | 2001-10-04 | — | — | WO | claimed |
| US-12595269-B2 | Morpholine-like monoamine releasers | Solvonis Therapeutics Ireland Holdings Limited (IE) | 2026-04-07 | — | — | US | disclosed |
| US-12590077-B2 | Short-acting monoamine releasers | Solvonics Therapeutics Ireland Holdings Limited (IE) | 2026-03-31 | — | — | US | disclosed |
| US-20250179089-A1 | BRIDGED RING COMPOUNDS AND THEIR THERAPEUTIC USE AS CNS AGENTS | AWAKN LS EUROPE HOLDINGS LIMITED (IE) | 2025-06-05 | — | — | US | disclosed |
| US-20250100990-A1 | 1,3-BENZODIOXOLE ESTERS AND THEIR THERAPEUTIC USE | AWAKN LS EUROPE HOLDINGS LIMITED (IE) | 2025-03-27 | — | — | US | disclosed |
| US-20240190809-A1 | THERAPEUTIC AMINOINDANE COMPOUNDS AND COMPOSITIONS | AWAKN LS EUROPE HOLDINGS LIMITED (IE) | 2024-06-13 | — | — | US | disclosed |
| US-11560365-B2 | Non-fluorescent rhodamines | THE UNIVERSITY OF TOKYO (JP) | 2023-01-24 | — | — | US | disclosed |
| WO-2002024689-A1 | ISOXAZOLIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DIABETES, HYPERLIPIDEMIA, AND ATHEROSCLEROSIS | ARYX THERAPEUTICS (US) | 2002-03-28 | — | — | WO | disclosed |
| US-20020025545-A1 | Monooxygenase assays | MONOGRAM BIOSCIENCES, INC. | 2002-02-28 | — | — | US | disclosed |
| US-20020009751-A1 | Drosophila homologues of genes and proteins implicated in metabolism and methods of use | EXELIXIS, INC. | 2002-01-24 | — | — | US | disclosed |
| WO-2001073113-A2 | MONOOXYGENASE ASSAYS | ACLARA BIOSCIENCES, INC. (US) | 2001-10-04 | — | — | WO | disclosed |
| EP-1119412-A2 | SAMPLE EVAPORATIVE CONTROL | Aclara BioSciences, Inc. (US) | 2001-08-01 | — | — | EP | disclosed |
| WO-2001014361-A1 | THE USE OF FLUORESCEIN ARYL ETHERS IN HIGH THROUGHPUT CYTOCHROME P450 INHIBITION ASSAYS | GENTEST CORPORATION (US) | 2001-03-01 | — | — | WO | disclosed |
| WO-2000067907-A2 | SAMPLE EVAPORATIVE CONTROL | ACLARA BIOSCIENCES, INC. (US) | 2000-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100990-A1 | 1,3-BENZODIOXOLE ESTERS AND THEIR THERAPEUTIC USE | DBH, TSPO, DDO | CYP3A4 97/4885PDE10A 1735/4885ALOX5 449/4885 |
| US-20240190809-A1 | THERAPEUTIC AMINOINDANE COMPOUNDS AND COMPOSITIONS | AADAT, PNMT, SLC1A2 | CYP3A4 1778/4885PDE10A 630/4885ALOX5 1281/4885 |
| US-12590077-B2 | Short-acting monoamine releasers | SLC6A2, NPY2R, SLC6A3 | CYP3A4 688/4885PDE10A 280/4885ALOX5 2084/4885 |
| US-12595269-B2 | Morpholine-like monoamine releasers | HTR3B, HTR3D, SLC6A3 | CYP3A4 1129/4885PDE10A 483/4885ALOX5 4765/4885 |
| US-20250179089-A1 | BRIDGED RING COMPOUNDS AND THEIR THERAPEUTIC USE AS CNS AGENTS | PNMT, SLC18A2, HTR2C | CYP3A4 551/4885PDE10A 1860/4885ALOX5 4288/4885 |
| US-11560365-B2 | Non-fluorescent rhodamines | QTRT1, QTRT2, NONO | CYP3A4 2537/4885PDE10A 4226/4885ALOX5 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.